BETA Beta Drugs Ltd Earnings Calls Announcement 2025 - H1 FY26 results Beta Drugs reports H1 FY26 revenue of ₹204 crores, EBITDA ₹47 crores with 23.08% margin, positive dermatology EBITDA; NSE main board migration expected within 10 days..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Beta Drugs Ltd